This is a crucial element for the construction of a future vaccine against GBM, particularly because we have already identified many new and potential GBM-specific tumor antigens in our recent studies on the characterization of the MHC-II immunopeptidome of human GBM cells transduced with CIITA (28). The gene discussed is CIITA; the disease is glioblastoma.